Potent antitumor activity of double-regulated oncolytic adenovirus-mediated ST13 for colorectal cancer

Cancer Science

Volumn 100, Issue 4, 2009, Pages 678-683

  Yu, De Bin ^a   Zhong, Su Yang ^a   Yang, Min ^a,d   Wang, Yi Gang ^a   Qian, Qi Jun ^a   Zheng, Shu ^c   Liu, Xin Yuan ^a,b  

^a ZHEJIANG SCI TECH UNIVERSITY   (China)

^b INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^c ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; CRYSTAL VIOLET; EOSIN; HEMATOXYLIN; SUPPRESSION OF TUMORIGENICITY 13; UNCLASSIFIED DRUG; BENZIMIDAZOLE DERIVATIVE; COLORING AGENT; FLUORESCENT DYE; HOE 33342; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; CANCER CELL CULTURE; CELL ASSAY; CELL VIABILITY; COLORECTAL CANCER; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG EFFICACY; DRUG SPECIFICITY; EXPRESSION VECTOR; FEMALE; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOHISTOCHEMISTRY; MOUSE; NICK END LABELING; NONHUMAN; NUCLEOTIDE SEQUENCE; NUDE MOUSE; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; TUMOR XENOGRAFT; ADENOVIRUS; ANIMAL; CELL DEATH; CELL STRAIN HCT116; CELL SURVIVAL; COLORECTAL TUMOR; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION; GENE THERAPY; GENE VECTOR; GENETICS; METABOLISM; METHODOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; BENZIMIDAZOLES; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; COLORECTAL NEOPLASMS; COLORING AGENTS; CYTOPATHOGENIC EFFECT, VIRAL; EOSINE YELLOWISH-(YS); FEMALE; FLUORESCENT DYES; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; GENTIAN VIOLET; HCT116 CELLS; HEMATOXYLIN; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MICE; MICE, NUDE; ONCOLYTIC VIROTHERAPY; TETRAZOLIUM SALTS; THIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67449099958     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01110.x     Document Type: Article

References (31)

1. Steward BW, Kleihues P (Eds): World Cancer Report. Lyon: IARC Press, 2003.
2. Wilke HJ, Van Cutsem E. Current treatments and future perspectives in colorectal and gastric cancer. Ann Oncol 2003; 14 (Suppl. 2): Ii49-55.
3. Penna C, Nordlinger B. Surgery of liver metastases from colorectal cancer: New promises. Br Med Bull 2002; 64: 127-40.
4. Alemany R, Balague C, Curiel DT. Replicative adenoviruses for cancer therapy. Nat Biotechnol 2000; 18: 723-7.
5. Heise C, Kirn DH. Replication-selective adenoviruses as oncolytic agents. J Clin Invest 2000; 105: 847-51.
6. Kim NW, Piatyszek MA, Prowse KR et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-15.
7. Kim E, Kim JH, Shin HY et al. Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. Hum Gene Ther 2003; 14: 1415-28.
8. Fujiwara T, Urata Y, Tanaka N. Diagnostic and therapeutic application of telomerase-specific oncolytic adenoviral agents. Front Biosci 2008; 13: 1881-6.
9. Hu ZB, Wu CT, Wang H et al. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes. Cancer Gene Ther 2008; 15: 173-82.
10. Safran M, Kaelin WG Jr HIF hydroxylation and the mammalian oxygen-sensing pathway. J Clin Invest 2003; 111: 779-83.
11. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-32.
12. Zhang Q, Chen G, Peng L et al. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus. Clin Cancer Res 2006; 12: 6523-31.
13. Liu XY, Gu JF. Targeting gene-virotherapy of cancer. Cell Res 2006; 16: 740.
14. Lee YS, Kim JH, Choi KJ et al. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model. Clin Cancer Res 2006; 12: 5859-68.
15. Zheng S, Cai X, Cao J. Application of subtractive hybridization in screening for colorectal cancer negatively related genes. Zhonghua Yi Xue Za Zhi 1997; 77: 256-9.
16. Mo Y, Zheng S, Shen D. Differential expression of HSU17714 gene in colorectal cancer and normal colonic mucosa. Zhonghua Zhong Liu Za Zhi 1996; 18: 241-3.
17. Dong QH, Zheng S, Hu Y, Chen GX, Ding JY. Evaluation of ST13 gene expression in colorectal cancer patients. J Zhejiang Univ Sci B 2005; 6: 1170-5.
18. Wang LB, Zheng S, Zhang SZ et al. Expression of ST13 in colorectal cancer and adjacent normal tissues. World J Gastroenterol 2005; 11: 336-9.
19. Hohfeld J, Minami Y, Hartl FU. Hip, a novel cochaperone involved in the eukaryotic Hsc70/Hsp40 reaction cycle. Cell 1995; 83: 589-98.
20. Prapapanich V, Chen S, Nair SC, Rimerman RA, Smith DF. Molecular cloning of human p48, a transient component of progesterone receptor complexes and an Hsp70-binding protein. Mol Endocrinol 1996; 10: 420-31.
21. Shi ZZ, Zhang JW, Zheng S. What we know about ST13, a co-factor of heat shock protein, or a tumor suppressor? J Zhejiang Univ Sci B 2007; 8: 170-6.
22. Hohfeld J, Jentsch S. GrpE-like regulation of the hsc70 chaperone by the anti-apoptotic protein BAG-1. EMBO J 1997; 16: 6209-16.
23. Irmer H, Hohfeld J. Characterization of functional domains of the eukaryotic co-chaperone Hip. J Biol Chem 1997; 272: 2230-5.
24. Yang M, Cao X, Yu MC et al. Potent antitumor efficacy of ST13 for colorectal cancer mediated by oncolytic adenovirus via mitochondrial apoptotic cell death. Hum Gene Ther 2008; 19: 343-53.
25. Brogan IJ, Khan N, Isaac K, Hutchinson JA, Pravica V, Hutchinson IV. Novel polymorphisms in the promoter and 5′ UTR regions of the human vascular endothelial growth factor gene. Hum Immunol 1999; 60: 1245-9.
26. Yeo EJ, Chun YS, Park JW. New anticancer strategies targeting HIF-1. Biochem Pharmacol 2004; 68: 1061-9.
27. Yin XM. Bid, a BH3-only multi-functional molecule, is at the cross road of life and death. Gene 2006; 369: 7-19.
28. Caruso JA, Reiners JJ Jr. Proteolysis of HIP during apoptosis occurs within a region similar to the BID loop. Apoptosis 2006; 11: 1877-85.
29. Hostetter DR, Loeb CR, Chu F, Craik CS. Hip is a pro-survival substrate of granzyme B. J Biol Chem 2007; 282: 27 865-74.
30. Seenath MM, Roberts D, Cawthorne C et al. Reciprocal relationship between expression of hypoxia inducible factor 1alpha (HIF-1alpha) and the pro-apoptotic protein bid in ex vivo colorectal cancer. Br J Cancer 2008; 99: 459-63.
31. Dong QH, Zheng S, Hu Y et al. Evaluation of ST13 gene expression in colorectal cancer patients. J Zhejiang Univ Sci B 2005; 16: 1170-5.